Patient-reported functioning in major depressive disorder

Abstract Background Restless arms syndrome (RAS) is characterized by uncomfortable aching or burning sensations in the arms. RAS is regarded as an upper limb variant of restless legs syndrome (RLS). The lack of specific diagnostic criteria makes it difficult to recognize the RAS. Therefore, RAS is usually neglected in clinical practice. Moreover, when a patient was diagnosed with RAS, the adjustment of medications was the first choice for doctors, which may make the patient’s condition unstable. Case presentation A 33-year-old woman was diagnosed with schizophrenia and major depressive disorder. Starting with 0.6 g/d amisulpride, 0.1 g/d quetiapine, 75 mg/d venlafaxine sustained-release tablets, the patient reported symptoms of RAS (itching arms) on the fourth day since the latest hospitalization. After ruling out other factors, her RAS was suspected to be induced by antidepressants or antipsychotics. Without medication adjustment, RAS spontaneously remitted. Conclusions This case suggests that psychiatrists should pay attention to RAS when using antipsychotics and/or antidepressants. Moreover, RAS may be transitory. When a patient manifests RAS, observation may be one choice instead of an immediate medication adjustment.

Download Full-text

PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

Value in Health ◽

10.1016/j.jval.2018.09.2887 ◽

2018 ◽

Vol 21 ◽

pp. S287

Author(s):

V. Bonthapally ◽

E. Suthoff ◽

P. Hodgkins ◽

H. Gunduz-Bruce ◽

R. Lasser ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Symptoms ◽

Depressive Disorder ◽

Controlled Trial ◽

Allosteric Modulator ◽

Phase 2 ◽

Positive Allosteric Modulator ◽

Major Depressive ◽

Patient Reported ◽

Patient Reported Measures

Download Full-text

Cognitive impairment in major depressive disorder

CNS Spectrums ◽

10.1017/s1092852918001207 ◽

2018 ◽

Vol 24 (1) ◽

pp. 22-29 ◽

Cited By ~ 7

Author(s):

Zihang Pan ◽

Caroline Park ◽

Elisa Brietzke ◽

Hannah Zuckerman ◽

Carola Rong ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Cognitive Dysfunction ◽

Cognitive Deficits ◽

Functional Disability ◽

Testable Hypothesis ◽

Major Depressive ◽

Cognitive Domains ◽

Patient Reported ◽

Neurobiological Substrates

Cognitive dysfunction is a symptomatic domain identified across many mental disorders. Cognitive deficits in individuals with major depressive disorder (MDD) contribute significantly to occupational and functional disability. Notably, cognitive subdomains such as learning and memory, executive functioning, processing speed, and attention and concentration are significantly impaired during, and between, episodes in individuals with MDD. Most antidepressants have not been developed and/or evaluated for their ability to directly and independently ameliorate cognitive deficits. Multiple interacting neurobiological mechanisms (eg, neuroinflammation) are implicated as subserving cognitive deficits in MDD. A testable hypothesis, with preliminary support, posits that improving performance across cognitive domains in individuals with MDD may improve psychosocial function, workplace function, quality of life, and other patient-reported outcomes, independent of effects on core mood symptoms. Herein we aim to (1) provide a rationale for prioritizing cognitive deficits as a therapeutic target, (2) briefly discuss the neurobiological substrates subserving cognitive dysfunction, and (3) provide an update on current and future treatment avenues.

Download Full-text